Latest & greatest articles for levofloxacin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levofloxacin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levofloxacin

1. ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients

ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients View/ Open Date 2009-01 Format (...) Metadata Abstract Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Strength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT). URI Part of Citation Journal of Family Practice, 58(1) 2009: 24+. Collections hosted by hosted by

2019 PURLS

2. Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS

Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS 30213322 2018 09 14 1558-3597 72 12 2018 Sep 18 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS. 1321-1329 S0735-1097(18)35591-8 10.1016/j.jacc.2018.06.069 The residual SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score (RSS (...) ) quantitatively assesses angiographic completeness of revascularization after percutaneous coronary intervention (PCI) and has been shown to be a predictor of events after angiography-guided PCI. In stable patients undergoing functionally complete revascularization with fractional flow reserve (FFR) guidance, RSS did not predict outcome. Whether this is also true in patients with acute coronary syndromes (ACS) is unknown. The purpose of this study was to determine whether the RSS could predict outcomes

2018 EvidenceUpdates

3. ACE inhibitors

ACE inhibitors Top results for ace inhibitors - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ace inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

2018 Trip Latest and Greatest

4. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial

Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial 29912422 2018 06 18 1522-9645 2018 Jun 14 European heart journal Eur. Heart J. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. 10.1093 (...) /eurheartj/ehy332 Guided de-escalation of P2Y12-inhibitor treatment was recently identified as an effective alternative treatment strategy in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention. Safety and efficacy of this strategy may differ in relation to patient's age. This pre-specified analysis of the TROPICAL-ACS trial aimed to assess the impact of age on clinical outcomes following guided de-escalation of antiplatelet treatment in ACS patients. Patients were

Full Text available with Trip Pro

2018 EvidenceUpdates

5. AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm

AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm ENDOCRINE PRACTICE Vol 24 No. 1 January 2018 91 AACE/ACE Consensus Statement CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY Alan J. Garber, MD, PhD, FACE 1 ; Martin J. Abrahamson, MD 2 ; Joshua I. Barzilay, MD, FACE 3 ; Lawrence Blonde, MD, FACP , MACE 4 ; Zachary T. Bloomgarden, MD (...) , Orange, California; 20 Professor of Medicine, Emory University School of Medicine, Director, Endocrinology Section, Grady Health System, Atlanta, Georgia. Address correspondence to American Association of Clinical Endocrinologists, 245 Riverside Avenue, Suite 200, Jacksonville, FL 32202. E-mail: publications@aace.com. DOI: 10.4158/CS-2017-0153 To purchase reprints of this article, please visit: www.aace.com/reprints. Copyright © 2018 AACE.92 2018 AACE/ACE T2D Management, Endocr Pract. 2018;24(No. 1

2018 American Association of Clinical Endocrinologists

6. Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial. (PubMed)

Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial. Importance: Wide heterogeneity exists in acute myocardial infarction treatment and outcomes in India. Objective: To evaluate the effect of a locally adapted quality improvement tool kit on clinical outcomes and process measures in Kerala, a southern Indian state. Design, Setting, and Participants: Cluster randomized, stepped-wedge

Full Text available with Trip Pro

2018 JAMA

7. Memalukan, AC Milan Dibantai Tim Yang Menghuni Zona Degradasi

Memalukan, AC Milan Dibantai Tim Yang Menghuni Zona Degradasi Memalukan, AC Milan Dibantai Tim Yang Menghuni Zona Degradasi - Medicalvideos Breaking News Fetching data... ☰ Navigation Memalukan, AC Milan Dibantai Tim Yang Menghuni Zona Degradasi Minggu, 07 Januari 2018 Newsnesia.net - Dengan banyaknya pemain yang didatangkan AC Milan pada musim ini tentunya para pendukung ingin melihat Milan yang seperti dulu kembali menguasai Liga Italia, namun sepertinya hal tersebut ternoda oleh pertandingan (...) ini. AC Milan secara mengejutkan kalah 0-3 dari tim zona degradasi, Hellas Verona dalam lanjutan Serie A di Stadio Marc'Antonio Bentegodi, Minggu 17 Desember 2017. AC Milan sebenarnya menguasai permainan. Namun mereka kesulitan membongkar pertahanan rapat tuan rumah. Tidak ada peluang berarti yang dibuat AC Milan. Skuat asuhan Gennaro Gattuso malah kebobolan di menit 24. Gol dicetak Antonio Caracciolo melalui sundulan memanfaatkan sepak pojok. Verona unggul 1-0. Di babak kedua, Milan coba bermain

2018 MedicalVideos

8. Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP?

Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes (...) and normal BP? View/ Open Date 2017-04 Format Metadata Abstract Q: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Evidence-based answer: Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor blockers (ARBs). In normotensive patients with type 1 and type 2 diabetes, ACE inhibitor therapy reduces the risk of developing diabetic kidney disease, defined as new-onset microalbuminuria or macroalbuminuria, by 18% (strength

2018 Clinical Inquiries

9. Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 20–22 September 2017 – Comité consultatif sur la vaccination et la recherché sur la mise en oeuvre des vaccins (IVIR-AC): ré

Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 20–22 September 2017 – Comité consultatif sur la vaccination et la recherché sur la mise en oeuvre des vaccins (IVIR-AC): ré WHO IRIS: Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 20–22 September 2017 – Comité consultatif sur la vaccination et la recherché sur la mise en oeuvre des (...) vaccins (IVIR-AC): résumé des conclusions et recommandations, 20-22 septembre 2017 Browse Related links Files in This Item: File Description Size Format 195.47 kB Adobe PDF Title: Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 20–22 September 2017 – Comité consultatif sur la vaccination et la recherché sur la mise en oeuvre des vaccins (IVIR-AC): résumé des conclusions et recommandations, 20-22 septembre 2017 Authors

2018 WHO

10. The Performance of CRUSADE and ACUITY Bleeding Risk Scores in Ticagrelor-Treated ACS Patients Who Underwent PCI

The Performance of CRUSADE and ACUITY Bleeding Risk Scores in Ticagrelor-Treated ACS Patients Who Underwent PCI 29044298 2017 12 20 2567-689X 117 11 2017 Nov Thrombosis and haemostasis Thromb. Haemost. The Performance of CRUSADE and ACUITY Bleeding Risk Scores in Ticagrelor-Treated ACS Patients Who Underwent PCI. 2186-2193 10.1160/TH17-04-0237 The performance of the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC (...) /AHA guidelines) and ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) risk scores for the prediction of major bleeding in ticagrelor-treated acute coronary syndrome (ACS) patients who underwent percutaneous coronary intervention (PCI) is unknown. The aim of the present study is to validate the performance of both scores in a contemporary Chinese cohort of ACS patients hospitalized for PCI and administrated with ticagrelor. From January 2013 to December 2014, a total of 629

2018 EvidenceUpdates

11. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. (PubMed)

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. BACKGROUND: Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity. METHODS: In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma

2017 Lancet

12. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. (PubMed)

ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. BACKGROUND: Among adolescents with type 1 diabetes, rapid increases in albumin excretion during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk factors for renal and cardiovascular disease. We hypothesized that adolescents with high levels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs that have not been fully evaluated (...) in adolescents. METHODS: We screened 4407 adolescents with type 1 diabetes between the ages of 10 and 16 years of age and identified 1287 with values in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a statin with the use of a 2-by-2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration of diabetes. The primary outcome for both interventions was the change in albumin excretion

Full Text available with Trip Pro

2017 NEJM

13. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. (PubMed)

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. BACKGROUND: Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous coronary intervention (PCI). However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent (...) , assessor-blinded, multicentre trial (TROPICAL-ACS) done at 33 sites in Europe, patients were enrolled if they had biomarker-positive acute coronary syndrome with successful PCI and a planned duration of dual antiplatelet treatment of 12 months. Enrolled patients were randomly assigned (1:1) using an internet-based randomisation procedure with a computer-generated block randomisation with stratification across study sites to either standard treatment with prasugrel for 12 months (control group

Full Text available with Trip Pro

2017 Lancet

14. Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study (PubMed)

Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study 28538984 2018 11 13 2380-6591 2 7 2017 Jul 01 JAMA cardiology JAMA Cardiol Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study. 750-757 10.1001/jamacardio.2017.1460 Pragmatic clinical trial designs have proposed the use of medical claims (...) year of the index acute myocardial infarction (MI) of 12 365 patients enrolled in the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study between April 1, 2010, and October 31, 2012. Fourteen patients (0.1%) died during the index hospitalization and were excluded from analysis. Recurrent MI, stroke, and bleeding events were identified per the International Classification of Diseases

Full Text available with Trip Pro

2017 JAMA cardiology

15. Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease (PubMed)

Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease 28713585 2018 11 13 2056-4724 3 4 2017 Jul BJPsych open BJPsych Open Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer's disease. 158-164 10.1192/bjpo.bp.116.004184 Cognitive improvement has been reported in patients receiving centrally acting angiotensin-converting enzyme inhibitors (C-ACEIs). To compare cognitive decline and survival after (...) diagnosis of Alzheimer's disease between people receiving C-ACEIs, non-centrally acting angiotensin-converting enzyme inhibitors (NC-ACEIs), and neither. Routine Mini-Mental State Examination (MMSE) scores were extracted in 5260 patients receiving acetylcholinesterase inhibitors and analysed against C-/NC-ACEI exposure at the time of Alzheimer's disease diagnosis. In the 9 months after Alzheimer's disease diagnosis, MMSE scores significantly increased by 0.72 and 0.19 points per year in patients on C

Full Text available with Trip Pro

2017 BJPsych open

16. Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice

Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Prescrire IN ENGLISH - Spotlight ''Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice'', 1 June 2017 {1} {1} {1} | | > > > Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Hypertension treatment in diabetes patients aims to reduce the risk of complications: cardiovascular events, end-stage renal failure, deterioration of eyesight. Patients with diabetes are exposed to arterial damage, including coronary artery disease and stroke, and damage to the blood capillaries

2017 Prescrire

17. ACE inhibitor‐associated intestinal angioedema in orthotopic heart transplantation (PubMed)

ACE inhibitor‐associated intestinal angioedema in orthotopic heart transplantation 28772029 2018 11 13 2055-5822 4 3 2017 Aug ESC heart failure ESC Heart Fail ACE inhibitor-associated intestinal angioedema in orthotopic heart transplantation. 384-386 10.1002/ehf2.12161 Angiotensin-converting enzyme inhibitor induced angioedema commonly involves the head and neck area. We report a case of angiotensin-converting enzyme inhibitor induced intestinal angioedema in a heart transplant recipient (...) on mTOR immunosuppression. A 36-year-old Caucasian woman with history of heart transplantation on sirolimus, tacrolimus and prednisone presented to the Emergency Department with abdominal pain, one day following lisinopril initiation. A computer tomography scan demonstrated diffuse bowel wall thickening consistent with pancolitis and edema. She was subsequently diagnosed with angiotensin-converting enzyme inhibitor induced angioedema. Patients on mTOR immunosuppression are at higher risk

Full Text available with Trip Pro

2017 ESC heart failure

18. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. (PubMed)

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. BACKGROUND: Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increased bleeding. The safety of a dual (...) , randomised trial (GEMINI-ACS-1) done at 371 clinical centres in 21 countries, eligible patients were older than 18 years with unstable angina, non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI), with positive cardiac biomarkers and either ischaemic electrocardiographic changes or an atherosclerotic culprit lesion identified during angiography. Participants were randomly assigned (1:1) within 10 days after admission for the index acute coronary

Full Text available with Trip Pro

2017 Lancet

20. ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus